The new kernel's number ends in zero, but it's not a milestone release. Linux 7.0 boasts improvements in Rust, its scheduler - and it's further embracing AI. More than half a dozen distros will let ...

One point in favor of the sprawling Linux ecosystem is its broad hardware support—the kernel officially supports everything from ’90s-era PC hardware to Arm-based Apple Silicon chips, thanks to ...

Torvalds and the Linux maintainers are taking a pragmatic approach to using AI in the kernel. AI or no AI, it's people, not LLMs, who are responsible for Linux's code. If you try to mess around with ...

Emirate sets regulatory framework to monitor, test, and safeguard public health Law No. 4 of 2026 strengthens preventive measures in public health establishments. Shutterstock Ras Al Khaimah: His ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

If your laptop is stranded on Windows 10, the solution isn’t a new laptop. It’s a new operating system. If you buy something from a Verge link, Vox Media may earn a commission. See our ethics ...

It's draft month, and there's one Clemson Tiger who could be rising up every team's draft board until everybody's name is called. Now, that agenda might be changing. In a metric titled “relative ...

An interministerial seminar convened on 8 April by the Directorate General for Enterprise, the National Agency for Information Systems Security, and the State Procurement Directorate produced a ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...